Supplementary Material - Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials

Supplementary Information to accompany and support the manuscript: Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trials配合并支撑该学术论文的补充资料：《迪尔戈昔替尼乳膏（delgocitinib cream）用于慢性手部湿疹成人患者最长52周的长期安全性与有效性——继DELTA 1、DELTA 2试验后的三期开放标签扩展DELTA 3试验结果》